For Thursday, February 2nd
EWSI
MNOV, DSCO, MDHI, MHYS, CTCC, CAMS
Our Stocks to Watch today include E-Waste Systems Inc. (OTCBB: EWSI), MediciNova Inc. (NASDAQ: MNOV), Discovery Laboratories Inc. (NASDAQ: DSCO), Medical Alarm Concepts Holding Inc. (OTCBB: MDHI), Mass Hysteria Entertainment Company Inc. (OTCBB: MHYS), City Capital Corp. (OTC: CTCC) and Cambrian Systems Inc. (OTC: CAMS).
FEATURED COMPANY
E- WASTE SYSTEMS INCORPORATED (OTC: EWSI)
Detailed Quote: http://www.otcpicks.com/quotes/EWSI.php
Company Profile: http://bit.ly/ykzje7
Headquartered in London, where e-waste regulations are the most stringent in the world, EWSI is becoming a leading provider of e-waste related services in key jurisdictions globally. Blumberg Associates estimates the sector at $55B annually as legislation mandates that e-waste can no longer be landfilled. OEM's, retailers and consumers are increasingly responsible for end-of-life management of e-waste, while Corporate Social Responsibility demands highly compliant, professional solution providers.
EWSI News:
February 1 - E-Waste Systems Enters Into Agreement With Zak Enterprises
Teaming Agreement to Provide International Customer Services
E-Waste Systems, Inc. (OTCBB: EWSI) announced that it has joined forces with Zak Enterprises of Santa Clara, CA to expand its geographic coverage with immediate customer services.
Zak Enterprises is based in the heart of Silicon Valley and is among the longest serving companies in the end of life electronics industry. The new agreement will allow seamless, best-in-class service delivery to customers of both companies with consistent, high quality standards. Product has already begun flowing from Zak customers in Europe through EWSI's network with more expected to follow.
EWSI's strategy includes acquiring and partnering with quality enterprises with innovative managements, who share the commitment to providing compliant, cost-effective and environmentally-responsible services for e-waste processing, reverse logistics and hardware recycling. Through partnerships, acquisitions, thought-leading business development, and Fair Trade E-waste solutions, EWSI expects to extend its reach and offering; to apply best practice professional management; and to invest in state-of-the-art technology.
"We are very please to link up with Kurt Schenk and his team at Zak," said EWSI's CEO Martin Nielson. "Our companies share the commitment to providing top quality end-of-life services and this agreement allows us both to expand our reach in that pursuit."
Mr. Schenk commented, "Our industry is consolidating and becoming more vertically integrated. We see this partnership as a way to leverage a global presence on behalf of our large enterprise customers."
The three-year agreement defines the quality services under offer; provides for full audit trails of all transactions; provides a mechanism for sharing economic benefit; requires periodic reviews; and includes non-disclosure and non-circumvention terms.
STOCKS TO WATCH
MEDICINOVA INCORPORATED (NASDAQ: MNOV)
"Up 34.39% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/MNOV.php
MediciNova, Inc. is a publicly traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a commercial focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential, and patent coverage of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus on its two prioritized product candidates, MN-221, for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations, and ibudilast (MN-166/AV411). Each drug candidate is involved in clinical trials under U.S. and Investigator INDs. MediciNova is engaged in strategic partnering discussions to support further development of the MN-221 and ibudilast programs. Additionally, MediciNova will seek to monetize opportunistically its other pipeline candidates.
MNOV News:
February 1 - MediciNova Receives a Notice of Patent Allowance for a Method of Treating Progressive Multiple Sclerosis
Claims Cover the Use of Ibudilast for Primary or Secondary Progressive Multiple Sclerosis
MediciNova Inc. (NASDAQ: MNOV), a biopharmaceutical company traded on the NASDAQ Global Market and the Jasdaq Market of the Osaka Securities Exchange (4875), announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers the use of ibudilast for the treatment of progressive forms of multiple sclerosis. Ibudilast (MN-166), is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, neuropathic pain, and drug addiction.
A patent maturing from this allowed patent application is expected to expire no earlier than early 2029 and covers a method of treating primary progressive multiple sclerosis (PPMS) or secondary progressive MS (SPMS) by administering ibudilast either alone or in combination with other drugs. The patent application is based upon clinical investigations conducted by MediciNova researchers which showed an apparent disease-modifying benefit in which brain volume loss, or brain atrophy, commonly associated with disease progression, was reduced by oral administration of ibudilast to a group of multiple sclerosis patients including some subjects with progressive multiple sclerosis, in a dose-related fashion over at least a 10-month treatment period.
Multiple sclerosis (MS) is recognized as a chronic disease in which disability progresses over time. Patients suffering from progressive forms of MS tend to have a poor prognosis and have greater levels of disability. Robert J. Fox, M.D., M.S., FAAN, Medical Director of Mellen Center for MS, Cleveland Clinic, noted that, "Despite recent improvements in pharmacotherapy for relapsing remitting multiple sclerosis, treatment options in progressive multiple sclerosis are extremely limited in the absence of relapses. There is great need for safe, effective, and conveniently-administered therapies for progressive MS."
Obtaining long-term protection of market exclusivity for the use of ibudilast in certain neurological conditions has been a key component of MediciNova's development strategy for the MN-166 program. Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, noted that, "We are very pleased to receive notice of this patent allowance for ibudilast in progressive MS. Moreover, we anticipate that this allowance will facilitate further development and business options around this program."
ABOUT IBUDILAST
Ibudilast has been used in asthma and post-stroke disorders in Japan for around 20 years. MediciNova has demonstrated the potential utility of ibudilast in the treatment of neurological disorders at higher doses with encouraging outcomes in company-sponsored clinical trials in multiple sclerosis (MS) and neuropathic pain. MediciNova's collaborative trial planning with drug addiction investigators at organizations like Columbia/NYSPI and UCLA has led to National Institute on Drug Abuse (NIDA)-to support clinical investigations of the use of ibudilast to treat both opioid and methamphetamine addiction. A Phase 2 investigator-sponsored trial of ibudilast in the treatment of chronic medication overuse headache (MOH) pain is also ongoing in Australia. MediciNova's priorities include pursuing Phase 2 proof-of-concept trials of ibudilast for the treatment of progressive MS and/or neuropathic pain through non-dilutive funding.
DISCOVERY LABS INCORPORATED (NASDAQ: DSCO)
"Up 14.35% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/DSCO.php
Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 Surfactant Technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary Capillary Aerosolization Technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs is focused initially on developing its KL4 surfactant pipeline to build a pediatric franchise that will potentially address several respiratory conditions affecting neonates and young children, beginning with Respiratory Distress Syndrome (RDS).
DSCO News:
February 2 - Discovery Labs Cleared to Market AFECTAIR in U.S.
New, Proprietary Technology Simplifies Delivery of Aerosolized Medications to Patients Requiring Ventilatory Support
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced AFECTAIR® is now registered with the Food and Drug Administration (FDA) and is cleared to be marketed in the United States. AFECTAIR is a proprietary patient interface technology that simplifies delivery of aerosolized medications to patients requiring ventilator support.
"We are pleased to have AFECTAIR registered with the FDA and we are eager to move this proprietary technology to commercialization in the latter part of 2012," said W. Thomas Amick, Chairman of the Board and Chief Executive Officer of Discovery Labs. "Our ability to bring AFECTAIR to market is a testament to our commitment to advancing a new standard in respiratory critical care."
AFECTAIR originates from the AEROSURF® development program and is a proprietary disposable ventilator circuit/patient interface connector that simplifies the delivery of aerosolized medications to critical-care patients requiring ventilatory support from either intermittent mechanical ventilation or continuous positive airway pressure. To date, in vitro studies suggest that the AFECTAIR technology may be an effective new solution for delivering aerosolized medicine to patients receiving ventilator support while providing healthcare professionals with a simplified alternative to current practices. According to national health statistics and market assessment data, it is estimated that each year more than 1.3 million patients in the United States and European Union receive aerosolized medications while requiring ventilator support. It is estimated that AFECTAIR represents a potential revenue opportunity of approximately $50-75 million for Discovery Labs.
"In preparation for this milestone, we identified a number of operational and commercial options intended to support the commercial introduction of AFECTAIR," said Thomas F. Miller, Senior Vice President and Chief Operating Officer of Discovery Labs, "We are now focused on implementing a commercial plan that includes the establishment of key strategic manufacturing and distribution relationships."
Discovery Labs is also pursuing a European Conformity (CE) marking for commercialization of the initial AFECTAIR products in the European Union (EU) and believes that it may be in a position to initiate the commercial introduction of the initial AFECTAIR products in EU in late 2012.
ABOUT AFECTAIR
AFECTAIR is a series of proprietary ventilator circuit/patient interface connectors and related componentry. AFECTAIR simplifies the delivery of inhaled therapies to critical care patients requiring ventilatory support. According to national health statistics and market assessment data, it is estimated that each year more than 1.3 million patients in the United States and European Union receive aerosolized medications while requiring ventilator support. Discovery Labs is implementing a business plan that potentially will allow for the commercial introduction of AFECTAIR in the United States and the European Union in 2012.
ABOUT AEROSURF
AEROSURF (lucinactant for inhalation), Discovery Labs' initial aerosolized KL4 surfactant product, is under development for the prevention of RDS in premature infants. Through effective delivery of aerosolized KL4 surfactant using Discovery Labs' proprietary capillary aerosol generator technology and related ventilator circuit / patient interface connectors, AEROSURF may significantly expand the surfactant-eligible treatment population by providing neonatologists with a means of administering surfactant without the risks currently associated with surfactant administration, which requires invasive endotracheal intubation and mechanical ventilation.
MEDICAL ALARM CONCEPTS HOLDING INCORPORATED (OTC: MDHI)
"Up 18.81% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/MDHI.php
Medical Alarm Concepts Holding Inc. (MAC) develops and manufactures innovative products and practical solutions within the framework of a vast growing marketplace. MediPendant's™ patented two-way voice technology enables the user to speak and listen directly through the pendant no matter where the user may be in and around their home. MediPendant™ service also includes advanced features such as three-way calling that enables the operator to link loved ones directly into the emergency call in real time. Text message alerts are also standard, and are used to inform loved ones that the user has contacted an operator or has requested assistance. A standard PERS system does not enable the user to speak and listen through the pendant, thus limiting them to a small area in their home. There is always the risk that the user will not be heard by the call center operator if they are not within a short range of the base station.
MDHI News:
January 31 - Medical Alarm to Begin Fulfillment of MediPendant™ Against Largest Purchase Order; Announces Additional Warrant Cancellations
Medical Alarm Concepts Holding, Inc. (OTCBB: MDHI) announced that it has received its first subsequent order as part of a large ongoing commitment the Company previously announced on November 21, 2011. This purchase order, which will be delivered in monthly installments throughout 2012, represents the company's single largest order to date.
"In November 2011, we announced a significant purchase order from one of our largest distribution partners," commented Ronald Adams, President of Medical Alarm Concepts. "We are very excited to announce that we have started to receive orders under this large contract, and that we are working with our manufacturing partner to significantly expand production of our patented MediPendant™ medical alarm device. We anticipate our profit from this contract will represent a substantial portion of our annual overhead. With our new television campaign launching this past weekend, and our other marketing programs in the works, we believe we are well-positioned to take market share in this robust and expanding space."
Mr. Adams continued, "Both end user customers and distributors are responding to our marketing message. With our patented, speak and listen through the pendant technology, we offer a superior medical alarm technology at a price that is highly competitive. We are expanding our distribution not only through the orders we are announcing today, but also via our partnerships with other vendors including Albertsons, Harrington Multimedia, and other big box and wholesale clubs. In addition, we now also have the financing arrangements in place to support our working capital needs in order to grow our business and expand shareholder value."
Medical Alarm Concepts recently announced a proposed merger with Carrollton, Texas-based FirstFitness Nutrition Inc., a leading provider of weight loss, wellness, and energy and fitness nutritional products. The combined operation is expected to produce over $12 million in revenues this year, and to yield both positive earnings and cash flow. Since the announcement of the proposed merger, revenues at FirstFitness have been accelerating due to increased interest in the weight loss category and enhancements to its marketing efforts. The companies have set February 28, 2012 as the proposed closing date for the merger.
In other news, the Company has been successful in negotiating the cancellation of an additional 10.5 million in money warrants, which is in addition to the cancellation of the 15.5 million in money warrants announced last week. The Company is expecting additional warrant cancellations and convertible debt cancellations over the next several weeks. These cancellations are part of an ongoing program to reduce shareholder dilution and to meaningfully improve the Company's balance sheet and future income statement performance.
ABOUT FIRSTFITNESS NUTRITION
FirstFitness Nutrition, headquartered in Carrollton, Texas is a leading provider of wellness, weight loss, and energy and fitness products. The Company has been in business for more than 20 years. Chairman of FirstFitness Nutrition, Lee Causey, is a pioneer in the weight loss and sports nutrition industries. In the early 1960s, he began to lay the groundwork for the first ever "diet shake," a product, which today is manufactured by hundreds of companies, and responsible for generating billions of dollars in sales worldwide.
Before long, Lee became known as a wellness expert to many celebrities, athletes and notable leaders. In the 70s, he broke new ground with the creation of his first nutritional company "Slender Now," which was touted by the Wall Street Journal as the fastest growing privately held company in history. He has since created more than 300 nutritional and weight loss products and, along with Nigel Branson, founded FirstFitness Nutrition in 1989. The Company distributes its products via a dynamic sales channel consisting of more than 5,000 dedicated men and women who market the products to consumers in all fifty U.S. states.
MASS HYSTERIA ENTERTAINMENT COMPANY (OTC: MHYS)
"Up 40.00% in morning trading"
Detailed Quote: www.otcpicks.com/quotes/MHYS.php
Mass Hysteria Entertainment, Inc. is a multi-media entertainment company created to produce films with an interactive component. The Company most recently completed production in Louisiana on CARJACKED starring Maria Bello and Stephen Dorff . Anchor Bay acquired domestic and English speaking territories and CMG is selling the picture internationally. Mass Hysteria also recently acquired the rights to the romantic comedy SLEEPING TOGETHER written by Steve Smith and Phill Traill and to be directed by Traill.
MHYS News:
November 28 - Mass Hysteria Entertainment Goes on the Run With 'BAD MONDAY' PR Newswire
Mass Hysteria Entertainment Company, Inc. (OTCBB: MHYS) has acquired the rights to BAD MONDAY, an action thriller written by Richard Taylor and being produced by Daniel Grodnik (POWDER, BOBBY) for Mass Hysteria Entertainment.
BAD MONDAY revolves around O.T. Mckee , a good guy from Michigan , with an estranged wife and kid and no job. Mckee gets kicked out of his house and finds himself wrapped up in a situation spiraling out of control with stolen cars, bags of money and running for his life.
Grodnik commented, "Richard's script is a high-octane ride that is extremely entertaining and that we believe will appeal to a world-wide audience." Taylor said, "Dan is an old friend and I am excited to work with him on this project. O.T. is just a guy who makes one wrong decision and finds himself caught up in an extraordinary situation. BAD MONDAY was designed to be the first of many O.T. adventures."
CITY CAPITAL CORPORATION (OTC: CTCC)
"Up 80.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/CTCC.php
City Capital Corporation, founded in 1984, is a leader in the production and distribution of emerging new gaming technology. Its holdings include corporate owned retail stores and partnerships across the nation. City Capital also maintains its long track-record of both building value for investors and shareholders, while keeping with its socially responsible focus. A significant share of profits are donated to charity and other worthwhile causes.
CTCC News:
January 12 - New Acquisition Offers Solar Power and LED Lighting Nationwide
Having a firm belief that Green Energy is a sound investment as a necessity for the world's future energy requirements, City Capital Corporation (OTC: CTCC) has acquired Strategic Energy and Power (STEP), a Nevada-based startup that manufactures, installs, sells and distributes solar installations and LED lighting. It also has proprietary technology that promises to be the future of the industry.
"The company is particularly enthused about its adaptation for terrestrial use of solar generators previously used only in space applications," said company CEO Donald MacIntyre. "We're also in the process of patenting a system that captures off-angle solar energy without the use of a tracking device that will allow much more efficient and inexpensive generation of solar power. Green Energy is still in its infancy, and we're excited about becoming a leader in this growth industry."
With distribution and installation agreements already in place, the company offers solar and LED installation for both residential and commercial applications around the country. Talks are upcoming with several Native American entities for systems to meet their needs, and plans are underway to bid competitively for governmental contracts.
CAMBRIAN SYSTEMS INCORPORATED (OTC: CAMS)
"Up 50.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/CAMS.php
Cambrian is an independent oil and gas company with a primary focus on acquiring, developing and participating in the U.S. crude oil and natural gas properties.
CAMS News:
January 18 - Cambrian Announces Corporate Update
Cambrian Systems (OTC: CAMS) announces that it is making very good progress in Kentucky.
As we stand today, Cambrian Systems is predominantly an independent oil and gas company with a primary focus on acquiring, developing and participating in crude oil and natural gas properties. The past four months have been highly productive for Cambrian. We now have acquired just over 500 acres of oil leases. Significant revenue opportunities exist through the development of the existing wells and the reactivation of the shut-in wells.
Currently, our operator has been carrying out appraisal and development studies. The principal objective of the 2012 work program is to assess and plan for the commercialization of our prospective resources and to explore ways to exploit these Wells with an early production scheme to generate early cash flows. The Company constantly reviews investment opportunities that will increase our exploration and production asset portfolio and will target value accretive acquisitions which may require additional funding in the future.
We are also proud to announce that within the next two weeks we expect to fully equip and put one well into production on our 250 acre King lease in Green County, Kentucky.
Over the ensuing weeks we'll be closely monitoring and working to maximize production from this well. Assuming we achieve commercially viable production amounts, we'll use the same production-enhancing techniques employed on this well as a blueprint as we move forward with equipping and getting production from other wells on our block of leases in Green County.
|
